LT3018132T - Kondensuoti imidazolo dariniai tinkami naudoti kaip ido inhibitoriai - Google Patents

Kondensuoti imidazolo dariniai tinkami naudoti kaip ido inhibitoriai

Info

Publication number
LT3018132T
LT3018132T LTEP15197593.5T LT15197593T LT3018132T LT 3018132 T LT3018132 T LT 3018132T LT 15197593 T LT15197593 T LT 15197593T LT 3018132 T LT3018132 T LT 3018132T
Authority
LT
Lithuania
Prior art keywords
imidazole derivatives
derivatives useful
ido inhibitors
fused imidazole
fused
Prior art date
Application number
LTEP15197593.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corporation filed Critical Newlink Genetics Corporation
Publication of LT3018132T publication Critical patent/LT3018132T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP15197593.5T 2011-04-15 2012-04-12 Kondensuoti imidazolo dariniai tinkami naudoti kaip ido inhibitoriai LT3018132T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15

Publications (1)

Publication Number Publication Date
LT3018132T true LT3018132T (lt) 2018-03-26

Family

ID=45976556

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15197593.5T LT3018132T (lt) 2011-04-15 2012-04-12 Kondensuoti imidazolo dariniai tinkami naudoti kaip ido inhibitoriai

Country Status (30)

Country Link
US (5) US9260434B2 (esLanguage)
EP (3) EP3018132B1 (esLanguage)
JP (4) JP2014511876A (esLanguage)
KR (1) KR102164443B1 (esLanguage)
CN (2) CN105111210B (esLanguage)
AU (4) AU2012242871C1 (esLanguage)
BR (1) BR112013026494A2 (esLanguage)
CA (1) CA2833296C (esLanguage)
CL (1) CL2013002990A1 (esLanguage)
CO (1) CO6862146A2 (esLanguage)
CY (1) CY1117440T1 (esLanguage)
DK (2) DK3018132T3 (esLanguage)
ES (2) ES2660831T3 (esLanguage)
HK (1) HK1256355A1 (esLanguage)
HR (2) HRP20160369T1 (esLanguage)
HU (2) HUE027316T2 (esLanguage)
IL (3) IL228862A (esLanguage)
LT (1) LT3018132T (esLanguage)
ME (1) ME02417B (esLanguage)
MX (1) MX340442B (esLanguage)
NO (1) NO2694640T3 (esLanguage)
NZ (2) NZ708090A (esLanguage)
PE (2) PE20181023A1 (esLanguage)
PL (2) PL3018132T3 (esLanguage)
PT (1) PT3018132T (esLanguage)
RS (2) RS54723B1 (esLanguage)
RU (2) RU2613579C2 (esLanguage)
SI (2) SI2697227T1 (esLanguage)
SM (1) SMT201600130B (esLanguage)
WO (1) WO2012142237A1 (esLanguage)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (esLanguage) 2011-04-15 2018-03-17
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9617272B2 (en) * 2013-03-14 2017-04-11 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
KR102189529B1 (ko) * 2013-03-14 2020-12-11 큐띌데람 파마 프띌읎ëȄ튾 멬믾티드 킀누레닌 êČœëĄœì˜ 얔제제
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (zh) * 2013-08-06 2015-06-03 äżĄćźžç”Ÿç‰©ćŒ»èŻïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž 侀种3-æ°Ż-7(5)-æșŽè‹Żćč¶ćŒ‚æ¶ć”‘çš„ćˆæˆæ–čæł•
AU2014369982B2 (en) 2013-12-24 2019-04-18 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizaçÔes dos mesmos
WO2016037026A1 (en) * 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 濅æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ÎČïŒČæ‹źæŠ—ćŠ‘
US10189902B2 (en) 2014-12-23 2019-01-29 Bristol-Myers Squibb Company Antibodies to TIGIT
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EA201792186A1 (ru) 2015-04-03 2018-03-30 Đ‘Ń€ĐžŃŃ‚ĐŸĐ»-МаĐčДрс ĐĄĐșĐČОбб ĐšĐŸĐŒĐżĐ°ĐœĐž Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ĐžĐœĐŽĐŸĐ»Đ°ĐŒĐžĐœ-2,3-ĐŽĐžĐŸĐșŃĐžĐłĐ”ĐœĐ°Đ·Ń‹ Đž ŃĐżĐŸŃĐŸĐ±Ń‹ ох ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžŃ
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
TWI698435B (zh) * 2015-04-10 2020-07-11 è‹±ć±Źé–‹æ›ŒçŸ€ćł¶ć•†ç™ŸæżŸç„žć·žæœ‰é™ć…Źćž 䜜ç‚șćČ據èƒș,-äșŒćŠ æ°§é…¶ć’Œ/或è‰Č氚酞,-äșŒćŠ æ°§é…¶æŠ‘ćˆ¶ćŠ‘äč‹æ–°ç©Žäč‹ïŒ•æˆ–-ć–ä»Łäč‹ć’Șć”‘äžŠïŒ»ïŒ‘ïŒŒïŒ•ïŒïœïŒœćĄć•¶
AU2016248366B2 (en) 2015-04-12 2019-06-13 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as IDO and TDO inhibitors
PL3283527T3 (pl) 2015-04-13 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworĂłw
US10899764B2 (en) 2015-04-21 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 æˆéƒœæ”·ćˆ›èŻäžšæœ‰é™ć…Źćž äž€ç§æ°˜ä»Łçš„idoæŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una CorporaciĂłn Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CN105037371A (zh) * 2015-06-30 2015-11-11 è„żćŽć€§ć­Š äž€ç§æ°˜ä»Łçš„ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
AU2016298471C1 (en) 2015-07-24 2020-03-05 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-D-tryptophan
KR20180034548A (ko) 2015-07-28 2018-04-04 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 Tgf ëȠ타 수용ìČŽ êžží•­ì œ
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2018525415A (ja) 2015-08-25 2018-09-06 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒŽïœ‡ïœ†ăƒ™ăƒŒă‚żć—ćźčäœ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
CN106478634B (zh) * 2015-09-01 2020-05-22 ć°šćŽćŒ»èŻç§‘æŠ€(æ±Ÿè„ż)æœ‰é™ć…Źćž 皠搈ć’Șć”‘ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ć’Œç”šé€”
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
EP3371208B8 (en) 2015-11-02 2024-10-23 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
HK1254241A1 (zh) * 2015-11-09 2019-07-12 F. Hoffmann-La Roche Ag ç”šæ–Œé‰Žćźšido1撌/或tdoè°ƒèŠ‚ć‰‚çš„ç­›é€‰æ”‹ćźšæł•
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
AU2016359609B2 (en) 2015-11-23 2023-12-07 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CN108602829A (zh) 2015-12-15 2018-09-28 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž Cxcr4ć—äœ“æ‹źæŠ—ć‰‚
US10800780B2 (en) * 2015-12-24 2020-10-13 Genentech, Inc. TDO2 Inhibitors
CN107056785B (zh) * 2016-01-02 2021-06-22 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
AU2017215424A1 (en) * 2016-02-02 2018-08-09 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3416725A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
KR20180128907A (ko) 2016-02-19 2018-12-04 ìč˜ì•„타읎 티안큉 íŒŒë§ˆìˆ˜í‹°ì»Ź ê·žëŁč ìŁŒì‹íšŒì‚Ź ë©Žì—­ìĄ°ì ˆì œëĄœì„œ 작용하는 íŠžëŠŹì‹œíŽëŠ­ í™”í•©ëŹŒ (tricyclic compound serving as immunomodulator)
TW201736373A (zh) * 2016-02-19 2017-10-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 䜜ç‚șć…ç–«èȘżçŻ€ćŠ‘çš„äž‰äžŠç’°ćŒ–ćˆç‰©
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CN105732643A (zh) * 2016-04-18 2016-07-06 è‹ć·žć€§ć­Š äž€ç§ć¶è”ç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćœšćˆ¶ć€‡idoé…¶æŠ‘ćˆ¶ć‰‚ć’Œéžç”Ÿäœ“æŠ—ç‚ŽèŻç‰©äž­çš„ćș”甚
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN107312005B (zh) * 2016-04-27 2021-12-17 äžŠæ”·çż°æŁźç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć…·æœ‰ido/tdoæŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
JP2019516682A (ja) 2016-05-04 2019-06-20 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”šæ–čæł•
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004743A (ko) 2016-05-04 2019-01-14 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
WO2017192840A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
CN109641874A (zh) 2016-05-10 2019-04-16 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„c3-çąłèżžæŽ„çš„æˆŠäșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN107556316B (zh) * 2016-06-30 2021-11-12 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN105902542A (zh) * 2016-05-16 2016-08-31 ćŒ é˜ł äž€ç§ć¶è”ç‰©ćœšćˆ¶ć€‡æČ»ç–—ćżƒèĄ€çźĄç–Ÿç—…èŻç‰©äž­çš„ćș”甚
CN107383012B (zh) * 2016-05-16 2021-09-28 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 搫äșŒçŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN106957318B (zh) * 2016-05-19 2019-12-10 äž­ć›œç§‘ć­Šé™ąäžŠæ”·æœ‰æœșćŒ–ć­Šç ”ç©¶æ‰€ çš ćˆć€šçŽŻćČć“šć•‰ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli Ù…Ű±ÙƒŰšŰ§ŰȘ 1-ŰȘيŰȘ۱ۧ Ù‡ÙŠŰŻŰ±ÙˆŰšÙŠŰ±Ű§Ù†ÙŠÙŠÙ„ ÙƒŰ§Ű±ŰšÙˆÙ†ÙŠÙ„ -2ی3-ŰŻÙŠÙ‡ÙŠŰŻŰ±Ùˆ -1 h- Ű§Ù†ŰŻÙˆÙ„ لŰčÙ„Ű§ŰŹ Ű§Ù„ŰłŰ±Ű·Ű§Ù†
CN107488179B (zh) * 2016-06-11 2024-06-07 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556315B (zh) * 2016-06-30 2021-08-31 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«ć››ć…ƒçŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
WO2018028491A1 (zh) * 2016-08-09 2018-02-15 è‹ć·žć›œćŒĄćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ćČ據èƒș23-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćœšèŻć­Šäž­çš„ç”šé€”
WO2018039518A1 (en) 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 ćčżć·žćż…莝ç‰čćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搫ć’Șć”‘çš ćˆäž‰çŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćș”甚
TW201815766A (zh) 2016-09-22 2018-05-01 çŸŽć•†æ™źé›·èŸ›è‚Żć…Źćž ç”šæ–Œïœ‰ïœ„ïœćŠïœ”ïœ„ïœèȘżçŻ€äč‹ćŒ–ćˆç‰©ćŠæ–čæł•ä»„ćŠć…¶é©æ‡‰ç—‡
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
MA50839A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
WO2018072743A1 (zh) * 2016-10-21 2018-04-26 è‹ć·žç››èżȘäșšç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž Pd-1抗䜓䞎idoæŠ‘ćˆ¶ć‰‚è”ćˆćœšćˆ¶ć€‡æŠ—è‚żç˜€çš„èŻç‰©äž­çš„ç”šé€”
CN108884099B (zh) * 2016-10-21 2021-10-08 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„æžžçŠ»çą±çš„ç»“æ™¶ćœąćŒćŠć…¶ćˆ¶ć€‡æ–čæł•
AU2017355603A1 (en) 2016-11-04 2019-06-20 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
CN106474468B (zh) * 2016-11-23 2020-03-27 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŒ»ć­Šç”Ÿç‰©ć­Šç ”ç©¶æ‰€ äž€ç§ć€ćˆäœć‰‚ă€ć«èŻ„ć€ćˆäœć‰‚çš„ç–«è‹—ćŠç–«è‹—çš„ćˆ¶ć€‡æ–čæł•
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
CN108203438B (zh) * 2016-12-20 2021-09-28 æ·±ćœłćŸźèŠŻç”Ÿç‰©ç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž ć…·æœ‰ćČ據èƒș2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘ćŒ–ćˆç‰©
MD3559009T2 (ro) 2016-12-22 2021-07-31 Calithera Biosciences Inc Compoziții și metode de inhibare a activității arginazei
CN108239091B (zh) * 2016-12-26 2021-08-13 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąèŻç‰©ç ”ç©¶æ‰€ 1-环深ćŸș-2-(5H-ć’Ș攑[5,1-a]ćŒ‚ćČ據)äč™ćŸș-1-é…źçš„æ‹†ćˆ†
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
US20200031944A1 (en) 2017-03-31 2020-01-30 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 抗icosäżƒæ•ˆćŠ‘æŠ—é«”ćŠć…¶ç”šé€”
CN110831600B (zh) 2017-04-21 2023-10-17 ćŒ»è‚Żçșłè‚żç˜€ć­Šć…Źćž ćČ據ahræŠ‘ćˆ¶ć‰‚ć’Œć…¶ç”šé€”
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 æˆéƒœæ”·ćšé”èŻäžšæœ‰é™ć…Źćž 侀种idoæŠ‘ćˆ¶ć‰‚ćŒ–ćˆç‰©ă€èŻç”šç»„ćˆç‰©ă€ç”šé€”
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
US11603373B2 (en) 2017-06-28 2023-03-14 Genentech, Inc. TDO2 and IDO1 inhibitors
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
ES2932354T3 (es) 2017-07-28 2023-01-18 Bristol Myers Squibb Co DinucleĂłtidos cĂ­clicos como agentes anticĂĄncer
CN111194232B (zh) 2017-08-02 2023-01-31 èŠćŠ ć“„ć€§ć­Š çșłç±łçș§é‡‘ć±žæœ‰æœșć±‚ć’Œé‡‘ć±žæœ‰æœșçșłç±łç‰‡
CN111183147B (zh) 2017-08-04 2024-07-05 æ‹œæ–Żç§‘æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž Cd137ç‰čćŒ‚æ€§çš„ćŒçŽŻè‚œé…äœ“
CN109983019B (zh) * 2017-08-08 2021-12-21 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„ćˆ¶ć€‡æ–čæł•
CN109384791B (zh) * 2017-08-09 2020-09-11 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©æžžçŠ»çą±çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
US11267824B2 (en) 2017-08-17 2022-03-08 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
US11236107B2 (en) 2017-08-18 2022-02-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of tricyclic compound
WO2019040102A1 (en) * 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
KR102651946B1 (ko) 2017-08-31 2024-03-26 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co DinucleĂłtidos cĂ­clicos como agentes anticancerosos
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 äž­ć›œèŻç§‘ć€§ć­Š ć’Ș攑ćč¶ćŒ‚ćČć“šç±»ido1æŠ‘ćˆ¶ć‰‚ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćș”甚
EP4176876A1 (en) 2017-09-14 2023-05-10 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
KR102885797B1 (ko) 2017-10-10 2025-11-12 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019078246A1 (ja) 2017-10-19 2019-04-25 äž€èˆŹç€Ÿć›Łæł•äșșăƒ•ă‚Ąăƒ«ăƒžăƒăƒŹăƒŒăƒ—ăƒ­ă‚žă‚§ă‚Żăƒˆæ”ŻæŽæ©Ÿæ§‹ ïŒ©ïœ„ïœïŒïœ”ïœ„ïœé˜»ćźłć‰€
KR20200074214A (ko) 2017-11-01 2020-06-24 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 암을 ìč˜ëŁŒí•˜ëŠ”데 ì‚Źìš©í•˜êž° 위한 멎역자ê·č 횚늄작용 항ìČŽ
ES2925450T3 (es) 2017-11-06 2022-10-18 Bristol Myers Squibb Co Compuestos de isofuranona Ăștiles como inhibidores de HPK1
CN111386114A (zh) 2017-11-25 2020-07-07 ç™Ÿæ”Žç„žć·žæœ‰é™ć…Źćž 䜜äžșćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„é€‰æ‹©æ€§æŠ‘ćˆ¶ć‰‚çš„æ–°éą–è‹Żćč¶ć’Ș攑
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN111886255B (zh) 2018-01-12 2025-04-04 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗tim3æŠ—äœ“ćŠć…¶ç”šé€”
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CA3087807A1 (en) 2018-01-15 2019-07-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž è„’ç±»ć’Œèƒç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ćœšćŒ»èŻäžŠçš„ćș”甚
KR20200116481A (ko) 2018-01-29 2020-10-12 메넎큏 파텐튾 êČŒì— ëȠ하 Gcn2 얔제제 및 읎의 용도
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ăŒă‚“ć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
CN112119072A (zh) 2018-03-20 2020-12-22 æ™źèŽ±ćžŒç§‘ć…Źćž 甹äșŽido撌tdoè°ƒèŠ‚çš„ćŒ–ćˆç‰©ć’Œæ–čæł•ïŒŒä»„ćŠć…¶é€‚ćș”ç—‡
TW201945393A (zh) 2018-03-21 2019-12-01 çŸŽć•†æˆŠç‘žæČ»ç™‚æœ‰é™ć…Źćž ćœšé…žæ€§pHç”ćˆè‡łVISTAäč‹æŠ—é«”
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
JP2021521182A (ja) 2018-04-12 2021-08-26 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒŁïœ„ïŒ—ïŒ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆăšïœïœ„âˆ’ïŒ‘ïŒïœïœ„âˆ’ïœŒïŒ‘è»žă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆăźç”„ăżćˆă‚ă›æȻ療
CA3096546A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
SI3814348T1 (sl) 2018-06-27 2023-10-30 Bristol-Myers Squibb Company Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic
HRP20230627T1 (hr) 2018-06-27 2023-09-29 Bristol-Myers Squibb Company Spojevi naftiridinona korisni kao aktivatori t ćelija
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞æČ»ç–—æœ‰é™ć…Źćž ćœšé…žæ€§pHäž‹ç»“ćˆè‡łVISTA的抗䜓
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
JP7455133B2 (ja) 2018-09-27 2024-03-25 ă‚·ă‚§ăƒłăƒă‚§ăƒł チップă‚čクăƒȘăƒŒăƒł ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ă‚ș ă‚«ăƒłăƒ‘ăƒ‹ăƒŒă€ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłæŽ»æ€§ă‚’æœ‰ă™ă‚‹ă‚­ăƒŽăƒ­ăƒłèȘ˜ć°Žäœ“
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
AU2019380307B2 (en) 2018-11-16 2026-01-29 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2022514618A (ja) 2018-12-21 2022-02-14 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ïŒ°ïœ„ïŒïœŒïŒ‘ă«ç‰č異的ăȘäșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
AU2020242284A1 (en) 2019-03-19 2021-09-16 FundaciĂł Privada Institut D'investigaciĂł OncolĂČgica De Vall Hebron Combination therapy for the treatment of cancer
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
EP3976192A1 (en) 2019-05-31 2022-04-06 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN114502158A (zh) 2019-06-28 2022-05-13 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Iraké™è§Łć‰‚ćŠć…¶ç”šé€”
CN114127066A (zh) 2019-07-11 2022-03-01 çˆ±æœè„żäșšèŻć“æœ‰é™ć…Źćž ćČ據èƒș2,3-ćŒćŠ æ°§é…¶ć’Œ/或è‰Čæ°šé…ž2,3-ćŒćŠ æ°§é…¶çš„æŠ‘ćˆ¶ć‰‚
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒšïœ…ïœŒïœ‰ïœïœ“ă‚żăƒłăƒ‘ă‚ŻèłȘăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘćŒ–ćˆç‰©
FI4065582T3 (fi) 2019-11-26 2025-05-25 Ikena Oncology Inc Polymorfisia karbatsolijohdannaisia ja niiden kÀyttötapoja
CN115151306A (zh) 2019-11-26 2022-10-04 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž (r)-n-(4-æ°Żè‹ŻćŸș)-2-((1s4s)-4-(6-氟ć–č敉-4-ćŸș)环深ćŸș)侙酰èƒș的盐/ć…±æ™¶
CN111333653A (zh) * 2019-12-16 2020-06-26 ć±±äžœć€§ć­Š 侀种icdèŻ±ćŻŒć‰‚-idoæŠ‘ćˆ¶ć‰‚çŒ€ćˆç‰©ćŠćˆ¶ć€‡æ–čæł•äžŽćș”甚
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
ES3013568T3 (en) 2019-12-23 2025-04-14 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
BR112022012222A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Derivados de piperazina substituĂ­dos Ășteis como ativadores de cĂ©lulas t
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
US12492172B2 (en) 2019-12-23 2025-12-09 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicĂ­clicos sustituidos Ăștiles como activadores de cĂ©lulas t
BR112022013424A2 (pt) 2020-01-06 2022-12-13 Hifibio Hk Ltd Anticorpo anti-tnfr2 e seus usos
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
US11534441B2 (en) 2020-01-15 2022-12-27 Blueprint Medicines Corporation MAP4K1 inhibitors
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2023516459A (ja) 2020-03-09 2023-04-19 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ćą—ćŒ·ă•ă‚ŒăŸă‚ąă‚Žăƒ‹ă‚čăƒˆæŽ»æ€§ă‚’æœ‰ă™ă‚‹ïœƒïœ„ïŒ”ïŒă«ćŻŸă™ă‚‹æŠ—äœ“
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
TW202140441A (zh) 2020-03-23 2021-11-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ćŸș異ćČć“šć•‰ćŒ–ćˆç‰©
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN111803635B (zh) * 2020-06-17 2023-03-14 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŸșçĄ€ćŒ»ć­Šç ”ç©¶æ‰€ ć°ćˆ†ć­æŠ‘ćˆ¶ć‰‚ćœšæČ»ç–—ć‘Œćžé“ç—…æŻ’æ€§è‚ș炎侊的ćș”甚
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
JP2023536462A (ja) 2020-07-30 2023-08-25 ă‚«ă‚€ăƒĄăƒ© ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ć€‰ç•°äœ“ăƒȘăƒłăƒ‘è…«ă‚’ć‡Šçœźă™ă‚‹æ–čæł•
CN116348476A (zh) 2020-08-03 2023-06-27 æ‹œæ–Żç§‘æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž ćŸșäșŽè‚œçš„掄怎
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cånceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
AU2021327130A1 (en) 2020-08-17 2023-03-02 Bicycletx Limited Bicycle conjugates specific for Nectin-4 and uses thereof
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3202330A1 (en) 2020-12-16 2022-06-23 Anthony Casarez Compounds useful as t cell activators
CA3202360A1 (en) 2020-12-30 2022-07-07 Nello Mainolfi Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP2024506339A (ja) 2021-02-12 2024-02-13 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ がんぼæČ»ç™‚ăźăŸă‚ăźäșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
KR20230145446A (ko) 2021-02-15 2023-10-17 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Irak4 분핎제 및 읎의 용도
EP4052705A1 (en) 2021-03-05 2022-09-07 UniversitÀt Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
JP2024510949A (ja) 2021-03-05 2024-03-12 ă‚Šăƒ‹ăƒŽă‚§ăƒ«ă‚·ă‚żăƒƒăƒˆăƒ»ăƒăƒŒă‚Œăƒ« ïŒ„ïœ‚ïœ–é–ąé€Łç–Ÿæ‚ŁćˆăŻçŠ¶æ…‹ăźæČ»ç™‚ç”šç”„æˆç‰©
JP2024510176A (ja) 2021-03-08 2024-03-06 ăƒ–ăƒ«ăƒŒăƒ—ăƒȘント ăƒĄăƒ‡ă‚Łă‚·ăƒłă‚ș ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ­ïœïœïŒ”ïœ‹ïŒ‘é˜»ćźłć‰€
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024515545A (ja) 2021-04-05 2024-04-10 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ がんæČ»ç™‚ăźăŸă‚ăźăƒ”ăƒȘă‚žăƒ‹ăƒ«çœźæ›ă‚Șă‚­ă‚œă‚€ă‚œă‚€ăƒłăƒ‰ăƒȘăƒłćŒ–ćˆç‰©
FI4320112T3 (fi) 2021-04-06 2025-07-25 Bristol Myers Squibb Co Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitÀ
MX2023011933A (es) 2021-04-09 2024-01-05 Nimbus Clio Inc Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
WO2023288264A1 (en) 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CN118103368A (zh) 2021-08-25 2024-05-28 çšźć…‹ćŒ»ç–—ć…Źćž Eif4eæŠ‘ćˆ¶ć‰‚ćŠć…¶ç”šé€”
MX2024005138A (es) 2021-10-29 2024-05-13 Kymera Therapeutics Inc Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos.
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2025527248A (ja) 2022-08-02 2025-08-20 ăƒȘăƒŸăƒŠăƒ«ăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș・ăƒȘミテッド çœźæ›ăƒ”ăƒȘăƒ‰ăƒłïœ‡ïœïœ’ïŒ˜ïŒ”ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆćŠăłăăźäœżç”š
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
CN120019047A (zh) 2022-08-02 2025-05-16 é‡Œç±łèŻșç”Ÿç‰©ç§‘ć­Šæœ‰é™ć…Źćž æ‚èŠłćŸșç”Č酰èƒș撌盾慳gpr84æ‹źæŠ—ć‰‚ćŠć…¶ç”šé€”
KR20250046309A (ko) 2022-08-08 2025-04-02 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 T ì„žíŹ í™œì„±í™”ì œëĄœì„œ 유용한 ìč˜í™˜ëœ í…ŒíŠžëŒìĄžëŠŽ í™”í•©ëŹŒ
JP2025528157A (ja) 2022-08-09 2025-08-26 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒŽçŽ°èƒžæŽ»æ€§ćŒ–ć‰€ăšă—ăŠæœ‰ç”šăȘçŹŹäž‰ă‚ąăƒŸăƒłçœźæ›äșŒç’°ćŒćŒ–ćˆç‰©
EP4568960A1 (en) 2022-08-11 2025-06-18 F. Hoffmann-La Roche AG Bicyclic tetrahydroazepine derivatives
PE20250876A1 (es) 2022-08-11 2025-03-28 Hoffmann La Roche Derivados biciclicos de tetrahidrotiazepina
EP4568746A1 (en) 2022-08-11 2025-06-18 F. Hoffmann-La Roche AG Bicyclic tetrahydrothiazepine derivatives
CR20250042A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados de tetrahidrotiazepina bicĂ­clicos
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 ćčżć·žćž‚è”ç‘žćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽŻçŁ·è…șè‹·æ‚èŽšçš„ćˆ¶ć€‡æ–čæł•
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN121057732A (zh) 2023-05-08 2025-12-02 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ç»ć–ä»Łçš„è‹ŻćŸșć™ć”‘é…źćŒ–ćˆç‰©
WO2024233900A1 (en) 2023-05-10 2024-11-14 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
CN121368591A (zh) 2023-05-31 2026-01-20 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 甹äșŽé™äœŽikzf 1-4蛋癜氎ćčłçš„ç»ć–ä»Łçš„ć™ć”‘é…źćŒ–ćˆç‰©
CN121487946A (zh) 2023-06-07 2026-02-06 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž èžșçŽŻć–ä»Łçš„æ°§ä»ŁćŒ‚ćČ據敉ćŸșć“Œć•¶-2,6-äșŒé…źćŒ–ćˆç‰©
US20250059164A1 (en) 2023-06-23 2025-02-20 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2024314878A1 (en) 2023-06-23 2026-01-22 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
KR20250068738A (ko) 2023-09-13 2025-05-16 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìč˜í™˜ëœ ì˜„ì†ŒìŽì†ŒìžëŒëŠŹë‹ í”ŒíŽ˜ëŠŹë”˜-2,6-디옚 í™”í•©ëŹŒ
TW202535865A (zh) 2023-10-31 2025-09-16 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž æł›çŽ ç‰čç•°æ€§ćŠ ć·„è›‹ç™œé…¶1 (usp1) ćŒ–ćˆç‰©
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
CN119707950A (zh) * 2024-12-24 2025-03-28 æ— é”Ąćž‚ć—äșŹć€§ć­Šé”Ąć±±ćș”ç”šç”Ÿç‰©æŠ€æœŻç ”ç©¶æ‰€ 侀种甹äșŽć…ç–«è›‹ç™œé¶ć‘é™è§Łçš„ć”Œćˆäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE40106T1 (de) 1983-05-18 1989-02-15 Ciba Geigy Ag Cyclohexandion-carbonsaeurederivate mit herbizider und das pflanzenwachstum regulierender wirkung.
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res NEW METHODS OF TREATING CANCER
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
EP1730148A4 (en) 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
RS54876B1 (sr) * 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
WO2008115804A1 (en) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 GrĂŒnenthal GmbH Substituierte Amid-Derivate
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
NZ586069A (en) 2007-12-19 2012-05-25 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2291187B1 (en) * 2008-04-24 2018-08-15 Newlink Genetics Corporation Ido inhibitors
SMT201800206T1 (it) 2008-07-08 2018-05-02 Incyte Holdings Corp 1,2,5-ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
NO2694640T3 (esLanguage) * 2011-04-15 2018-03-17
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9617272B2 (en) 2013-03-14 2017-04-11 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
KR102189529B1 (ko) 2013-03-14 2020-12-11 큐띌데람 파마 프띌읎ëȄ튾 멬믾티드 킀누레닌 êČœëĄœì˜ 얔제제
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
MA38483A1 (fr) 2013-03-15 2018-02-28 Bristol Myers Squibb Co Inhibiteurs de l'ido
JP6313416B2 (ja) 2013-03-15 2018-04-18 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒ©ïœ„ïœé˜»ćźłć‰€
ES2719327T3 (es) 2013-07-01 2019-07-09 Bristol Myers Squibb Co Inhibidores de IDO
CN105517999B (zh) 2013-07-11 2019-06-28 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž IdoæŠ‘ćˆ¶ć‰‚

Also Published As

Publication number Publication date
EP3348558A1 (en) 2018-07-18
HUE027316T2 (en) 2016-10-28
US20160362412A1 (en) 2016-12-15
CL2013002990A1 (es) 2014-07-04
DK3018132T3 (en) 2018-03-12
US20180118753A1 (en) 2018-05-03
US10233190B2 (en) 2019-03-19
PE20181023A1 (es) 2018-06-27
AU2014274564A1 (en) 2015-01-22
EP2697227A1 (en) 2014-02-19
AU2014274564B2 (en) 2016-10-06
HK1223371A1 (en) 2017-07-28
DK2697227T3 (en) 2016-04-25
AU2016277574B2 (en) 2018-04-19
AU2018202706A1 (en) 2018-05-10
JP6145491B2 (ja) 2017-06-14
CA2833296C (en) 2020-12-08
NZ723271A (en) 2018-03-23
NZ616457A (en) 2015-05-29
AU2012242871C1 (en) 2017-02-02
MX2013012021A (es) 2014-07-10
US20140066625A1 (en) 2014-03-06
RU2017107026A (ru) 2019-01-23
RS54723B1 (sr) 2016-08-31
AU2012242871A8 (en) 2013-11-21
AU2012242871A1 (en) 2013-10-31
PT3018132T (pt) 2018-03-09
US20160002249A1 (en) 2016-01-07
SI3018132T1 (en) 2018-04-30
MX340442B (es) 2016-07-08
US9850248B2 (en) 2017-12-26
CN103547579A (zh) 2014-01-29
RU2017107026A3 (esLanguage) 2019-01-23
WO2012142237A8 (en) 2012-11-22
ME02417B (me) 2016-09-20
CN105111210B (zh) 2018-10-09
EP2697227B1 (en) 2016-02-03
KR102164443B1 (ko) 2020-10-12
US9388191B2 (en) 2016-07-12
HK1256355A1 (en) 2019-09-20
SI2697227T1 (sl) 2016-06-30
WO2012142237A1 (en) 2012-10-18
HUE038586T2 (hu) 2018-10-29
KR20140059167A (ko) 2014-05-15
US20190225618A1 (en) 2019-07-25
RS56992B1 (sr) 2018-05-31
IL228862A0 (en) 2013-12-31
CA2833296A1 (en) 2012-10-18
IL241846A (en) 2016-06-30
JP2016029092A (ja) 2016-03-03
RU2613579C2 (ru) 2017-03-17
ES2569665T3 (es) 2016-05-12
EP3018132B1 (en) 2017-12-13
NZ708090A (en) 2016-12-23
EP3018132A1 (en) 2016-05-11
PE20141124A1 (es) 2014-09-06
PL3018132T3 (pl) 2018-05-30
IL246515B (en) 2018-08-30
JP2017149769A (ja) 2017-08-31
JP2015061877A (ja) 2015-04-02
NO2694640T3 (esLanguage) 2018-03-17
HRP20180335T1 (hr) 2018-04-20
ES2660831T3 (es) 2018-03-26
JP2014511876A (ja) 2014-05-19
RU2013150811A (ru) 2015-05-20
CO6862146A2 (es) 2014-02-10
IL241846A0 (en) 2015-11-30
HRP20160369T1 (hr) 2016-06-03
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
AU2012242871B2 (en) 2014-09-11
CN105111210A (zh) 2015-12-02
CN103547579B (zh) 2017-02-15
CY1117440T1 (el) 2017-04-26
AU2016277574A1 (en) 2017-01-12
IL228862A (en) 2015-10-29
JP5837673B2 (ja) 2015-12-24
US9260434B2 (en) 2016-02-16
HK1193822A1 (zh) 2014-10-03
BR112013026494A2 (pt) 2016-12-27

Similar Documents

Publication Publication Date Title
IL246515B (en) Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL233366A0 (en) Tetra or penta pyridophthalazinones are conjugated as parp inhibitors
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
IL233365A0 (en) Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
IL258704B (en) History of hydantoins used as kv3 inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL247638B (en) History of heteroaryl piperidine
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en) imidazole
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
PT2721009E (pt) Derivados de pirazole Ășteis como inibidores de aldosterona sintase
HK1186463A (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives